Studies have shown that drugs can reduce the levels of IL-6 and IL-1β by inhibiting STAT3 expression, thereby ameliorating liver inflammation [58]; targeting the STAT3 signaling pathway is considered an attractive therapeutic strategy for the development of anti-inflammatory drugs [59, 60]. The gene discussed is IL1B; the disease is inflammation.